APA (7th ed.) Citation

Santoni-Rugiu, E., Grauslund, M., Melchior, L. C., Costa, J. C., Sørensen, J. B., & Urbanska, E. M. (2017). Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Lung Cancer (01695002), 113, 14. https://doi.org/10.1016/j.lungcan.2017.08.024

Chicago Style (17th ed.) Citation

Santoni-Rugiu, Eric, Morten Grauslund, Linea C. Melchior, Junia C. Costa, Jens B. Sørensen, and Edyta M. Urbanska. "Heterogeneous Resistance Mechanisms in an EGFR Exon 19-mutated Non-small Cell Lung Cancer Patient Treated with Erlotinib: Persistent FGFR3-mutation, Localized Transformation to EGFR-mutated SCLC, and Acquired T790M EGFR-mutation." Lung Cancer (01695002) 113 (2017): 14. https://doi.org/10.1016/j.lungcan.2017.08.024.

MLA (9th ed.) Citation

Santoni-Rugiu, Eric, et al. "Heterogeneous Resistance Mechanisms in an EGFR Exon 19-mutated Non-small Cell Lung Cancer Patient Treated with Erlotinib: Persistent FGFR3-mutation, Localized Transformation to EGFR-mutated SCLC, and Acquired T790M EGFR-mutation." Lung Cancer (01695002), vol. 113, 2017, p. 14, https://doi.org/10.1016/j.lungcan.2017.08.024.